Skip to Main Content

Evaluating the role of opioid medication assisted therapies in HIV-1 Persistence

  • Study HIC#:2000023013
  • Last Updated:07/15/2021

The purpose of this study is to develop ways to examine how HIV stays in your body after someone starts medication assisted therapy (MAT) (e.g. buprenorphine/naloxone, buprenorphine, methadone or extended-release naltrexone), for the treatment of opioid use disorder, and to see how different types of MAT changes how HIV in the body.

The researchers will follow all participants and schedule regular interviews and blood draws to gather information. This will enable them to look at the presence of specific factors associated with HIV and treatment for opioid use disorder over time.  The study will last for 3 months.

  • Age18 years and older
  • GenderBoth
  • Start Date10/22/2018
  • End Date04/30/2023

Trial Purpose and Description

To develop methods to examine HIV-1 expression, proviral landscape and genomic architecture in response to different forms of MAT. To examine how different forms MAT changes HIV-1 persistence using viral and host genome mapping. 

Eligibility Criteria

The researchers will follow all participants and schedule regular interviews and blood draws to gather information. This will enable them to look at the presence of specific factors associated with HIV and treatment for opioid use disorder over time. The study will last for 3 months.

Eligibility Criteria:
a) Have a problem with opioids (heroin or prescription pain medications)
b) starting medication assisted therapy (MAT) for your opioid use disorder (buprenorphine/naloxone, buprenorphine, methadone or extended-release naltrexone)
c) have HIV; and
d) you are 18 years of age or older.

No healthy volunteers 

Principal Investigator

Sub-Investigators

For more information about this study, contact:

Or contact the Help us Discover team on: